A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.
Original languageEnglish
Article number577932
JournalJournal of neuroimmunology
Publication statusPublished - 15 Sep 2022


  • Adaptive immune receptor repertoire
  • Anti-drug antibody
  • B-cell receptor
  • Interferon beta
  • Multiple sclerosis
  • Next generation sequencing

Cite this